<br>        Inclusion criteria:<br><br>          -  Advanced (unresectable or metastatic) carcinoid tumor<br><br>          -  Confirmed low-grade or intermediate-grade neuroendocrine carcinoma<br><br>          -  Documented progression of disease within 12 months prior to randomization.<br><br>          -  Measurable disease determined by triphasic computer tomography (CT) scan or magnetic<br>             resonance imaging (MRI).<br><br>        Exclusion criteria:<br><br>          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,<br>             adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.<br><br>          -  Hepatic artery embolization within the last 6 months or cryoablation of hepatic<br>             metastasis within 2 months of enrollment.<br><br>          -  Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus,<br>             temsirolimus, everolimus)<br><br>          -  Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.<br><br>          -  Severe or uncontrolled medical conditions<br><br>          -  Chronic treatment with corticosteroids or other immunosuppressive agent.<br><br>          -  Other primary cancer within 3 years.<br><br>        Other protocol-defined inclusion/exclusion criteria applied<br>      ;<br>        Inclusion criteria:<br><br>          -  Advanced (unresectable or metastatic) carcinoid tumor<br><br>          -  Confirmed low-grade or intermediate-grade neuroendocrine carcinoma<br><br>          -  Documented progression of disease within 12 months prior to randomization.<br><br>          -  Measurable disease determined by triphasic computer tomography (CT) scan or magnetic<br>             resonance imaging (MRI).<br><br>        Exclusion criteria:<br><br>          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,<br>             adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.<br><br>          -  Hepatic artery embolization within the last 6 months or cryoablation of hepatic<br>             metastasis within 2 months of enrollment.<br><br>          -  Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus,<br>             temsirolimus, everolimus)<br><br>          -  Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.<br><br>          -  Severe or uncontrolled medical conditions<br><br>          -  Chronic treatment with corticosteroids or other immunosuppressive agent.<br><br>          -  Other primary cancer within 3 years.<br><br>        Other protocol-defined inclusion/exclusion criteria applied<br>      ;<br>        Inclusion criteria:<br><br>          -  Advanced (unresectable or metastatic) carcinoid tumor<br><br>          -  Confirmed low-grade or intermediate-grade neuroendocrine carcinoma<br><br>          -  Documented progression of disease within 12 months prior to randomization.<br><br>          -  Measurable disease determined by triphasic computer tomography (CT) scan or magnetic<br>             resonance imaging (MRI).<br><br>        Exclusion criteria:<br><br>          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,<br>             adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.<br><br>          -  Hepatic artery embolization within the last 6 months or cryoablation of hepatic<br>             metastasis within 2 months of enrollment.<br><br>          -  Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus,<br>             temsirolimus, everolimus)<br><br>          -  Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.<br><br>          -  Severe or uncontrolled medical conditions<br><br>          -  Chronic treatment with corticosteroids or other immunosuppressive agent.<br><br>          -  Other primary cancer within 3 years.<br><br>        Other protocol-defined inclusion/exclusion criteria applied<br>      ;<br>        Inclusion criteria:<br><br>          -  Advanced (unresectable or metastatic) carcinoid tumor<br><br>          -  Confirmed low-grade or intermediate-grade neuroendocrine carcinoma<br><br>          -  Documented progression of disease within 12 months prior to randomization.<br><br>          -  Measurable disease determined by triphasic computer tomography (CT) scan or magnetic<br>             resonance imaging (MRI).<br><br>        Exclusion criteria:<br><br>          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,<br>             adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.<br><br>          -  Hepatic artery embolization within the last 6 months or cryoablation of hepatic<br>             metastasis within 2 months of enrollment.<br><br>          -  Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus,<br>             temsirolimus, everolimus)<br><br>          -  Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.<br><br>          -  Severe or uncontrolled medical conditions<br><br>          -  Chronic treatment with corticosteroids or other immunosuppressive agent.<br><br>          -  Other primary cancer within 3 years.<br><br>        Other protocol-defined inclusion/exclusion criteria applied<br>